Addyi vs Low-Dose Testosterone for Women: Cost and Access Head-to-Head

What Are These Two Treatments and Why Does the Distinction Matter?

Low libido in women is not a single, simple problem. Hypoactive sexual desire disorder (HSDD) is the most studied clinical label, defined as persistent low desire that causes personal distress, and it affects an estimated one in ten premenopausal women. The treatment field splits into two pharmacologically distinct strategies: rebalancing central neurotransmitters (Addyi) or supplementing a hormone that declines with age and surgical menopause (testosterone).

Choosing between them is not just a question of which works better on paper. It is a question of your hormonal status, your reproductive plans, your prescriber's comfort level, your wallet, and whether you can live with specific restrictions.

No direct head-to-head randomized trial comparing flibanserin and low-dose testosterone has been published. Every comparison in this article is synthesized from separate trial programs and guideline documents.

How Addyi (Flibanserin) Works

Flibanserin acts on serotonin 1A and 2A receptors and dopamine D4 receptors in the prefrontal cortex. It is not a hormone. Think of it as retuning a neurochemical dial: it dampens serotonin's inhibitory effect on sexual desire while nudging dopamine and norepinephrine upward. It requires daily dosing at bedtime and takes four to eight weeks before any benefit becomes noticeable.

How Low-Dose Testosterone Works

Testosterone is an androgen that women produce in the ovaries and adrenal glands. Levels decline sharply after surgical menopause and gradually across the menopause transition. Applying a small amount of testosterone topically restores circulating free testosterone toward the physiological range seen in reproductive-age women, which in turn supports genital sensitivity, desire, and arousal through both peripheral and central pathways.

Efficacy: What the Trial Data Actually Show

Both treatments produce modest, statistically significant improvements over placebo. Neither produces dramatic, across-the-board results.

The Flibanserin Evidence: BEGONIA and Beyond

The BEGONIA trial was a 24-week phase III randomized controlled trial in premenopausal women with HSDD. Women taking flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events (SSEs) compared with placebo, along with reductions in distress scores. The mean increase in SSEs was approximately 0.5 to 1 additional satisfying event per month above placebo, a number that sounds small but was clinically meaningful to women who reported zero or near-zero events at baseline.

Across the four phase III trials that supported FDA approval, the benefit over placebo was consistent but modest. About 8% to 13% more women on flibanserin than on placebo were considered responders on global impression scales.

Because the trials enrolled premenopausal women specifically, the FDA label is restricted to that group. Using Addyi in postmenopausal women is off-label and less well characterized.

The Testosterone Evidence: The 2019 Global Consensus

The 2019 International Consensus on the Use of Testosterone for Women, a collaboration between The Menopause Society (formerly NAMS), the British Menopause Society, and seven other professional bodies, reviewed 36 randomized controlled trials. The consensus found that testosterone therapy at doses that restore physiological female levels produces a statistically significant improvement in sexual desire, arousal, orgasm, and overall sexual function, primarily in postmenopausal women.

The mean improvement in sexual function scores across trials was significantly greater than placebo, though the absolute magnitude was again moderate. The consensus explicitly states that evidence is strongest for postmenopausal women and weaker for premenopausal women, where fewer trials exist.

Comparing Efficacy Across Populations

| Population | Flibanserin evidence | Testosterone evidence | |---|---|---| | Premenopausal | Strong (direct RCT data) | Limited (extrapolated or small trials) | | Perimenopausal | Sparse, off-label | Moderate (included in some consensus trials) | | Postmenopausal | Off-label, limited data | Strongest evidence base | | Surgically menopausal | Off-label | Supported by consensus |

If you are premenopausal, flibanserin has the stronger regulatory and trial backing. If you are postmenopausal or surgically menopausal, testosterone has the stronger evidence base.

Cost and Access: The Real-World Gap

This is where the comparison becomes starkly practical.

Addyi Cost and Insurance Coverage

Addyi's list price sits around $840 to $1,200 per month at retail pharmacies, depending on location. Most commercial insurance plans do not cover it. The manufacturer, Sprout Pharmaceuticals, operates a savings program that can reduce the out-of-pocket cost for commercially insured patients to as little as $25 to $99 per month, but that program excludes government payers such as Medicaid and Medicare. Women without commercial insurance face the full price.

Addyi also carries an FDA Risk Evaluation and Mitigation Strategy (REMS) program. Prescribers must complete a certification, and patients must read and acknowledge the medication guide before dispensing. This adds an administrative layer that some smaller practices or telehealth platforms find burdensome, narrowing the prescriber pool.

Testosterone Cost and Access

No FDA-approved testosterone product exists for women in the United States. The two options are:

Compounded preparations. A compounding pharmacy can prepare testosterone in concentrations and vehicles appropriate for women: typically 0.5% to 2% cream or gel applied to the inner arm, thigh, or labia. Monthly cost ranges from roughly $30 to $150 depending on the pharmacy, formulation, and dose. These preparations are not FDA-approved, which means batch-to-batch potency can vary, and insurance rarely covers them.

AndroGel / Testim off-label. Some prescribers write for a fraction of a male-dosed commercial testosterone product. This approach delivers inconsistent microgram-level dosing and is not standard of care, though it is used.

Access to testosterone depends entirely on finding a prescriber willing to prescribe off-label. Gynecologists, reproductive endocrinologists, and menopause specialists trained in the 2019 Global Consensus recommendations are more likely to be comfortable with this. A primary care physician without specific training in women's sexual health may decline.

Side-by-Side Cost Summary

| | Addyi (flibanserin) | Low-dose testosterone | |---|---|---| | Monthly list price | $840, $1,200 | $30, $150 (compounded) | | With manufacturer savings card | $25, $99 (commercial insurance only) | N/A | | Insurance coverage | Rare | Rarely covered (off-label) | | REMS / prescriber certification | Yes | No | | Telehealth accessibility | Growing; requires REMS-certified prescriber | Depends on state telehealth prescribing rules |

Life-Stage Guide: Who Is Each Treatment Best Suited For?

Reproductive Years (Menstruating, Not Trying to Conceive)

Addyi has its best evidence here. If you are premenopausal, not pregnant, not planning pregnancy, and able to abstain completely from alcohol, flibanserin is the only FDA-approved option for your life stage.

Testosterone in premenopausal women is used off-label and supported by limited data. Small studies suggest benefit, but the 2019 consensus explicitly notes that evidence in premenopausal women is insufficient to make a recommendation. Cycle effects on baseline testosterone also make dosing and monitoring more complex.

Trying to Conceive

Neither treatment is appropriate if you are actively trying to conceive. See the pregnancy and lactation section below.

Perimenopause

Perimenopause is a grey zone for both treatments. Flibanserin's label covers premenopausal women, but the definition of perimenopause is hormonal flux rather than a clean pre/post boundary. If you are still menstruating, even irregularly, some prescribers consider you premenopausal enough for Addyi.

Testosterone evidence is more applicable here. Testosterone levels begin declining in the late 30s and drop further during perimenopause. A prescriber with menopause-specialist training may reach for low-dose testosterone as perimenopause progresses, particularly if other menopausal symptoms coexist and are being managed with estrogen.

Postmenopause and Surgical Menopause

This is testosterone's strongest territory. The 2019 Global Consensus recommends testosterone for postmenopausal women with HSDD when other causes have been excluded. Addyi is off-label in this group with no strong trial data. If you had a bilateral oophorectomy and lost testosterone production abruptly, the case for testosterone replacement as physiological repletion is particularly strong.

Restrictions, Side Effects, and What Daily Life Looks Like

Addyi: The Alcohol Prohibition

The most life-altering restriction for Addyi is the complete prohibition on alcohol. Combining flibanserin with alcohol causes severe hypotension and syncope. The FDA mandates this warning prominently. If you drink any alcohol at all, Addyi is functionally incompatible with your lifestyle as long as you are on it. This is not a "limit to one drink" instruction. It is a full abstinence requirement.

Additional common side effects include dizziness, somnolence, nausea, and fatigue, particularly in the first four weeks. Flibanserin is a CYP3A4 substrate, meaning dozens of common medications and even grapefruit juice can raise plasma levels and amplify these effects. Your prescriber should conduct a full medication review before starting.

Testosterone: Monitoring and Androgenic Effects

Low-dose testosterone is generally well tolerated when kept within the physiological female range. The main concerns are androgenic side effects: acne, increased body hair (hirsutism), and, rarely, clitoral sensitivity changes. These are dose-dependent and largely reversible on stopping.

Monitoring serum total testosterone (and sometimes free testosterone, sex hormone-binding globulin, and hematocrit) every three to six months during dose titration is standard. The 2019 consensus specifies that doses should target the upper end of the normal physiological female range, not supraphysiological levels. Transfer to children or male partners via skin contact is a real risk with cream or gel formulations; washing hands and covering the application site matter.

Long-term safety data beyond 24 months remain limited, and the consensus acknowledges this gap. Breast cancer safety specifically has not been established in large prospective trials.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety

Both treatments are contraindicated in pregnancy. This is not a precautionary hedge; it is based on specific harm signals and pharmacological reasoning.

Addyi in Pregnancy and Lactation

Flibanserin is classified as FDA Pregnancy Category not formally assigned post-2015 labeling change, but the prescribing information states that animal studies showed embryo-fetal toxicity and the drug is not recommended in pregnancy. Human pregnancy data are absent because pregnancy was an exclusion criterion in all trials. If you become pregnant while taking Addyi, stop it and contact your provider immediately.

Lactation data are also absent. Flibanserin distributes into lipid-rich tissues and its transfer into breast milk has not been studied. Given the CNS activity of the drug, breastfeeding while taking Addyi is not recommended.

Reliable contraception is required for any woman of reproductive age using Addyi. Hormonal contraceptives that inhibit CYP3A4 (such as oral contraceptives containing fluconazole or certain azole antifungals co-administered) can raise flibanserin exposure, so your prescriber should review your full contraceptive and medication list.

Testosterone in Pregnancy and Lactation

Testosterone is a known teratogen. Exogenous androgens in the first trimester cause virilization of female fetuses, and exposure at any gestational stage carries risk. The 2019 consensus explicitly states that testosterone must not be used in women who are pregnant or planning pregnancy.

Because low-dose transdermal testosterone may not be reliably detected by standard home pregnancy tests until several weeks after conception, women of reproductive age using testosterone should use highly effective contraception. Barrier methods alone are not considered sufficient given the teratogenic risk. An IUD, implant, or sterilization provides more reliable protection.

Testosterone transfer into breast milk is poorly studied. Given the androgenic effects on a nursing infant, testosterone is generally avoided during lactation.

What If You Have PCOS, Endometriosis, or Other Hormone-Sensitive Conditions?

PCOS

Women with polycystic ovary syndrome already have elevated androgens in many cases. Adding exogenous testosterone to a woman with PCOS and existing hyperandrogenemia risks worsening acne, hirsutism, and metabolic markers. A thorough androgen panel before prescribing testosterone is mandatory. Flibanserin, which is not androgenic, may be a safer starting point for premenopausal women with PCOS and HSDD, though no PCOS-specific trial data exist for either drug.

Endometriosis and Fibroids

Neither drug has been specifically studied in women with endometriosis or uterine fibroids. Testosterone is not estrogen-dependent and does not directly stimulate endometriotic lesions, though clinical experience in this group is limited. Flibanserin's non-hormonal mechanism means it does not interact with estrogen-dependent pathways.

Thyroid Disease

Women with hypothyroidism, which is far more common in women than men, should know that sex hormone-binding globulin levels affected by thyroid status can shift free testosterone levels even without a dose change. Monitoring should account for thyroid stability.

Switching From Addyi to Low-Dose Testosterone (and Vice Versa)

Switching is medically straightforward because there is no cross-taper requirement. Flibanserin is cleared within a few days of stopping. Testosterone requires a few weeks to wash out meaningfully.

Practically, switching requires finding a prescriber willing to prescribe whichever option you are moving to, which can itself be a barrier for testosterone. The common reasons women switch from Addyi to testosterone are alcohol incompatibility, persistent side effects (dizziness, fatigue), cost without a savings card, and a change in menopausal status that makes testosterone more evidence-aligned.

Women moving the other direction, from testosterone to Addyi, are typically premenopausal women who received testosterone off-label and want to try an FDA-approved option, or who developed androgenic side effects they found bothersome.

Who This Is Right For (and Who It Is Not)

Addyi Is Most Likely the Right Conversation If:

• You are premenopausal with a confirmed HSDD diagnosis
• You do not drink alcohol or are willing to stop entirely
• You have commercial insurance and can access the manufacturer savings card
• You want an FDA-approved medication with a defined regulatory track record
• Your provider is REMS-certified or works on a platform that handles REMS

Addyi Is Less Likely to Fit If:

• You drink alcohol socially and do not want to stop
• You are postmenopausal
• You are paying out of pocket and the savings card is not available to you
• You take multiple CYP3A4-interacting medications

Low-Dose Testosterone Is Most Likely the Right Conversation If:

• You are postmenopausal or surgically menopausal with low desire and distress
• You have a prescriber trained in The Menopause Society guidelines
• You are comfortable with off-label therapy and compounding pharmacy logistics
• Your baseline androgen levels are low or low-normal on testing
• You want a lower monthly out-of-pocket cost

Low-Dose Testosterone Is Less Likely to Fit If:

• You have PCOS with existing hyperandrogenemia
• You are premenopausal and hoping to conceive in the near future
• You have an active hormone-sensitive malignancy
• You cannot access a prescriber familiar with female testosterone dosing

Evidence Gaps Specific to Women

Women have been chronically under-represented in pharmacological research. For Addyi, the trial populations were almost exclusively cisgender, heterosexual, premenopausal women in committed relationships; how the drug performs in other populations is not established. For testosterone, most large trials enrolled postmenopausal women, so premenopausal and perimenopausal data are extrapolated from smaller studies or inferred from physiology.

The 2019 Global Consensus explicitly flags that long-term breast cancer and cardiovascular safety data for testosterone in women are insufficient. The authors note this is a priority research gap, not a reassurance that safety is established. Be direct with your provider about this uncertainty when making your decision.